ClinicalTrials.Veeva

Menu

Safety and Efficacy of the BTL-703 Treatment for the Non-invasive Lipolysis

BTL logo

BTL

Status

Unknown

Conditions

Overweight
Obesity

Treatments

Device: BTL-703 (Treatment group)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03545360
BTL-703-001

Details and patient eligibility

About

The study will evaluate safety and efficacy of the BTL-703 device for the non-invasive lipolysis.

Enrollment

52 estimated patients

Sex

All

Ages

22+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥ 22 years
  • Voluntarily signed informed consent form

Exclusion criteria

  • Implanted electronic device such as a cardiac pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, etc.
  • Diabetics dependent on insulin or oral hypoglycemic medications
  • Known cardiovascular disease such as arrhythmias, congestive heart failure
  • Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers.
  • Prior surgical interventions for body sculpting of thighs or buttocks such as liposuction
  • Medical, physical or other contraindications for body sculpting/ weight loss
  • Current use of medication known to affect weight levels and/or cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent
  • Any medical condition known to affect weight levels and/or to cause bloating or swelling
  • Active infection, wound or other external trauma to the area to be treated
  • Pregnant, breast feeding, or planning pregnant before the end of the study
  • Serious mental health illness
  • Active or recurrent cancer or current chemotherapy and/or radiation treatment
  • Negative affection to heat

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

52 participants in 1 patient group

Treatment Group
Experimental group
Description:
Treated group of subjects, serves as its own control
Treatment:
Device: BTL-703 (Treatment group)

Trial contacts and locations

1

Loading...

Central trial contact

Georgi Petkov

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems